Search

Aggression has different conceptualizations and can be behaviorally expressed in diverse ways. Designed to evaluate impulsive and premeditated forms of aggression, the Impulsive/Premeditated Aggression Scale (IPAS; Stanford et al., 2003) is a 30 item self-report questionnaire. The aim of the present study was to explore IPAS versatility in different psychological settings by reviewing and examining the exploratory psychometric prop- erties of the IPAS impulsive and premeditated subscales, across different samples and cultural backgrounds. Fifty-two articles including demographic or psychometric information (internal consistency, factor analysis, validity, reliability) were retrieved. It is suggested that the IPAS is reliable across different cultures, samples and scoring techniques. The two subscales (Impulsive and Premeditated) show acceptable internal consistency. Also, IPAS factors seem to be constant both in clinical and non-clinical samples. The IPAS appears to be a clinically useful instrument for differentiating between subtypes of aggressive behavior, to support risk assessment eva- luations, pretrial decisions and better treatment and rehabilitation strategies in offenders and clinical relevant samples., This work was supported by The Foundation for Science and Technology (Grant number SFRH/BD/76062/2011), and the Portuguese Ministry of Science, Technology and Higher Education through national funds and co-financed by FEDER and COMPETE2020 under the PT2020 Partnership Agreement (POCI-01-0145-FEDER007653) - Psychology Research Centre (UID/PSI/01662), awarded to the first author. The study was also supported by Grant SFRH/BPD/108602/2015 from the Portuguese Foundation for Science and Technology awarded to Andreia de Castro-Rodrigues.

article i nfo Available online 30 April 2013 The present study assessed the quality of pharmacotherapy trials to treat impulsive aggressive behavior. While a search of the literature found 55 peer-reviewed published studies on the pharmacotherapy of aggression, only 23 met criteria for inclusion in the quality analysis. To be included in this review, the study must have had at least one comparison group to control for placebo effects. The study must have also adequately defined and diag- nosed the presence of impulsive aggression or intermittent explosive disorder. The primary reason studies were excluded from the quality analysis was that impulsive aggression was not specifically defined as the behavior being treated (25 of 32, 78%). The results of the quality analysis found that higher quality studies (n =1 0; 45%) were characterized by a clear definition of impulsive aggression; specific criteria for what constitutes an impulsive aggressive act; the exclusion of participants with neurological disorders, serious mental disorders, and/or low IQ; and information concerning the serum levels ofthe medication being investigated. A significant weakness found in the literature is the paucity of high quality studies accessing the efficacy of pharmacological agents other than an- ticonvulsants for the treatment of impulsive aggression.